CG Oncology (CGON) Change in Acquisitions & Divestments (2023 - 2026)

CG Oncology's Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $252.9 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments rose 26.34% year-over-year to $252.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $896.9 million (up 12.15% YoY) and the FY2025 annual result came in at $844.1 million, up 13.24% from the prior year.
• Change in Acquisitions & Divestments was $252.9 million for Q1 2026 at CG Oncology, up from $222.2 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $252.9 million in Q1 2026 and bottomed at $30.7 million in Q3 2023.
• A 4-year average of $191.2 million and a median of $201.2 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments soared 556.36% — and 2025, when it declined 2.6%.
• CG Oncology's Change in Acquisitions & Divestments stood at $230.0 million in 2023, then retreated by 0.81% to $228.2 million in 2024, then fell by 2.6% to $222.2 million in 2025, then increased by 13.77% to $252.9 million in 2026.
• Business Quant data shows CGON's Change in Acquisitions & Divestments at $252.9 million in Q1 2026, $222.2 million in Q4 2025, and $251.4 million in Q3 2025.